---
layout: post
title: "Classification Categories for Certain Supplements Under Biosimilar User Fee Amendments III; Guidance for Industry; Availability"
date: 2026-02-04 21:49:16 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-17290
original_published: 2025-09-09 00:00:00 +0000
significance: 8.00
---

# Classification Categories for Certain Supplements Under Biosimilar User Fee Amendments III; Guidance for Industry; Availability

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** September 09, 2025 00:00 UTC
**Document Number:** 2025-17290

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Classification Categories for Certain Supplements Under BsUFA III." This guidance provides recommendations for applicants on classification categories A, B, C, D, E, and F for original and resubmitted prior approval supplements submitted to approved applications for biosimilar and interchangeable biosimilar products under the Public Health Service Act (PHS Act). The commitment letter associated with the Biosimilar User Fee Amendments of 2022 (BsUFA III) sets forth these supplement classification categories and their associated review performance goals. This guidance is intended to help applicants identify the appropriate classification category and review goal date of the supplement being submitted. This guidance finalizes and replaces the draft guidance of the same title issued on August 11, 2023.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/09/09/2025-17290/classification-categories-for-certain-supplements-under-biosimilar-user-fee-amendments-iii-guidance)
- API: https://www.federalregister.gov/api/v1/documents/2025-17290

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
